Havana, Wednesday 17 de July de 2019 06:47 pm

BioCubaFarma carries out more than 400 research projects

Tamaño letra:

Eduardo Martínez Díaz, presidente del grupo empresarial BioCubaFarma. Photo: Omara García Mederos
HAVAN, Cuba, Jul 18 (ACN) The BioCubaFarma business group, made up of 34 companies, works on 422 research projects aimed at the prevention and treatment of cancer, cardiovascular and neurodegenerative diseases, among others, explained its directors today in this capital.
Eduardo Martínez Díaz, president of BioCubaFarma, informed the specialized press that of this total, 393 are product-oriented and 29 are technological, and one of the mega-projects is the program of therapeutic molecules for neurodegenerative diseases such as Alzheimer's, Parkinson's and multiple sclerosis.
Named NeuroEpo, this product, developed by the Center for Molecular Immunology, has been shown to have a neuro-protective effect, he said.
Experts have clarified that although the drug does not prevent Alzheimer's, nor does it eliminate it, due to the good results in experimental phases, significant advances can be expected.
With a closed-loop line from research and development to production and commercialization, BioCubaFarma also has among its projects the CIGB- 500, promoted by the Center for Genetic Engineering and Biotechnology.
Currently in clinical trials, this cardio-protective product is able to reduce the size of the infarcted area by 78.9 percent in acute myocardial infarction, which proves its worth considering that cardiovascular diseases are the leading cause of death in Cuba.      
BioCubafarma, created five years ago, has among its missions the production of high-tech medicines, equipment and services and produces 62 percent of the items that make up the basic table of essential medicines for various diseases, consisting of 761 products, 486 of them of national production.
In order to guarantee good human health, this institution is also responsible for providing equipment, reagents, diagnostic media and products for dental use in pharmacies, polyclinics, hospitals and institutes.
Eduardo Martínez Díaz and directors of several of his entities explained the results of the five years of creation and projections of this industry, whose scientific development strategy is to respond to the main health problems of the Cuban population, and includes the prevention of infectious diseases and the detection of congenital malformations.

Add comment

Security code

Find Us:

our agency

We have over 130 experenced news professionals in 17 offices that give coverage to the entire national territory. (See more)